RE: Turnover up; losses up29 Sep 2022 10:32
The operating loss increased 6.5% to £359,114 (2021: £337,040)
Cash and cash equivalents at 30 June 2022 of £687,674 (30 June 2021: £1,043,450) (no mention of current cash figure)
Only two noteworthy contracts year to date in 2022 (last one in April)
Nothing new on DoseMeRX
Nothing new on VAL
On 7th March they disclosed "the Company has a strong pipeline of projects in advanced discussion" - can't be that far advanced!!!
More jam tomorow!!